We also have peptides for immunity (Thymosin Alpha-1, Epitalon) in our offer, which support the immune systems functioning, making the body more resistant to diseases
Semaglutide (Ozempic, Wegovy) maintains market leadership with 94.3% market share in 2025, but faces competitive pressure from Eli Lilly's tirzepatide (Mounjaro, Zepbound) demonstrating superior weight loss of 20 to 22% compared to Semaglutide's 10 to 17% in head-to-head trials
Currently, Semaglutide is undergoing clinical trials to investigate its effectiveness in treating Non-Alcoholic Fatty Liver Disease which is also known as Metabolic Dysfunction associated steatotic liver disease, with US FDA approval pending
Consistency over the full protocol duration matters more than individual dose precision
Clinical data shows that continuous treatment produces sustained results, while stopping often leads to weight regain within months